Last reviewed · How we verify

anti PD-1 with nab-paclitaxel

Fudan University · Phase 1 active Small molecule Quality 15/100

anti PD-1 with nab-paclitaxel is a Small molecule drug developed by Fudan University. It is currently in Phase 1 development. Also known as: SHR1210.

At a glance

Generic nameanti PD-1 with nab-paclitaxel
Also known asSHR1210
SponsorFudan University
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about anti PD-1 with nab-paclitaxel

What is anti PD-1 with nab-paclitaxel?

anti PD-1 with nab-paclitaxel is a Small molecule drug developed by Fudan University.

Who makes anti PD-1 with nab-paclitaxel?

anti PD-1 with nab-paclitaxel is developed by Fudan University (see full Fudan University pipeline at /company/fudan-university).

Is anti PD-1 with nab-paclitaxel also known as anything else?

anti PD-1 with nab-paclitaxel is also known as SHR1210.

What development phase is anti PD-1 with nab-paclitaxel in?

anti PD-1 with nab-paclitaxel is in Phase 1.

What are the side effects of anti PD-1 with nab-paclitaxel?

Common side effects of anti PD-1 with nab-paclitaxel include Anaemia, Neutrophil count decreased, White blood cell count decreased, Alopecia, Platelet count decreased, Alanine aminotransferase increased.

Related